![Peter Kiener](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Kiener
Président chez
Resolve Therapeutics LLC
Fortune : 263 $ au 31/05/2026
Profil
Peter Alec Kiener was the founder of Zyngenia, Inc., founded in 2009, where the titles held included President, Chief Executive Officer & Director from 2009 to 2013.
Current jobs include Chairman at Resolve Therapeutics LLC; Director at AbCellera Boston, Inc.; Director at Wugen, Inc. since 2021; Director at Peptone Ltd. since 2022; Venture Partner at Bridge Valley Ventures LLP; and Venture Partner at Intermediate Capital Group Plc (Private Equity) since 2021.
Former jobs include Chief Executive Officer at Cereius, Inc. from 2019 to 2020; Director at GT Biopharma, Inc. from 2018 to 2019; Director at Receptor BioLogix, Inc.; Director at Adheron Therapeutics, Inc.; Independent Non-Executive Director at LAVA Therapeutics NV from 2023 to 2025; Director at Virdante Pharmaceuticals, Inc.; Director at Viral Logic Systems Technology Corp.; Director at Cirius Therapeutics, Inc. from 2019 to 2021; Independent Director at Cue Biopharma, Inc. from 2020 to 2026; Director at Itolerance, Inc. from 2001 to 2024; Director at TetraGenetics, Inc. from 2015 to 2022; Independent Director at Pieris Pharmaceuticals, Inc. from 2018 to 2024; Head-Global Research & Development at Bristol Myers Squibb Co. from 1983 to 2001; Executive Vice President-Research & Development at MedImmune LLC; Executive Vice President at AstraZeneca PLC in 2009; Principal at the University of Oxford; Assistant Professor at the University of North Texas from 1982 to 1983; Research Associate at the University of Massachusetts from 1978 to 1982; Chief Science Officer at Ambrx, Inc. from 2013 to 2014; and Chief Scientific Officer at Sucampo Pharmaceuticals LLC from 2014 to 2018.
Education includes a doctorate from the University of Oxford conferred in 1978 and an undergraduate degree from the University of Lancaster conferred in 1973.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/05/2026 | 12 ( 0 % ) | 263 $ | 31/05/2026 |
Postes actifs de Peter Kiener
| Sociétés | Poste | Début |
|---|---|---|
Resolve Therapeutics LLC
 Resolve Therapeutics LLC BiotechnologyHealth Technology Develops biotechnology drugs | Président | - |
AbCellera Boston, Inc.
 AbCellera Boston, Inc. BiotechnologyHealth Technology Produces vaccines for plant, animal and human diseases | Directeur/Membre du Conseil | - |
Bridge Valley Ventures LLP
 Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures invests in companies located in the UK, Europe and North America. The firm focuses on oncology, neuroscience, immunology and rare diseases therapeutics, pharma/biotech sector. They provide financing for buyout transaction. | Private Equity Investor | - |
Wugen, Inc.
 Wugen, Inc. Packaged SoftwareTechnology Services Develops CAR-T therapy platform for cancer therapies | Directeur/Membre du Conseil | 01/07/2021 |
Intermediate Capital Group Plc (Private Equity)
 Intermediate Capital Group Plc (Private Equity) Investment ManagersFinance ICG invests in companies located across the globe primarily in Western Europe and North America regions. The firm focuses across a broad range of sectors and industries. It participates in the form of mezzanine, debt and equity for buyouts, restructuring transactions, recapitalizations and whole-fund liquidity solutions. | Private Equity Investor | 01/01/2021 |
Peptone Ltd.
 Peptone Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products and provides business, domestic software development, data processing, hosting and biotechnology research and development services | Directeur/Membre du Conseil | 01/01/2022 |
Anciens postes connus de Peter Kiener
| Sociétés | Poste | Fin |
|---|---|---|
| CUE BIOPHARMA, INC. | Président | 01/04/2020 |
| LAVA THERAPEUTICS N.V. | Directeur/Membre du Conseil | 07/11/2025 |
| PIERIS PHARMACEUTICALS | Directeur/Membre du Conseil | 13/12/2024 |
| ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Peter Kiener
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
82
Relations au 1er degré
27
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 27 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
MedImmune LLC
 MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
GT Biopharma, Inc.
 GT Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Engages in the discovering, developing and commercializing novel therapeutics | Health Technology |
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Receptor BioLogix, Inc.
 Receptor BioLogix, Inc. BiotechnologyHealth Technology Offers receptor based biological therapeutics | Health Technology |
Adheron Therapeutics, Inc.
 Adheron Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company | Health Technology |
AbCellera Boston, Inc.
AbCellera Boston, Inc. BiotechnologyHealth Technology Produces vaccines for plant, animal and human diseases | Health Technology |
Virdante Pharmaceuticals, Inc.
 Virdante Pharmaceuticals, Inc. Medical DistributorsDistribution Services Develops and commercializes drugs | Distribution Services |
Zyngenia, Inc.
 Zyngenia, Inc. Drugstore ChainsRetail Trade Develops new class of biotherapeutics | Retail Trade |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of North Texas
 University of North Texas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Massachusetts
 University of Massachusetts Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Lancaster
 University of Lancaster Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ambrx, Inc.
 Ambrx, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Sucampo Pharmaceuticals LLC
 Sucampo Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures prostone based pharmaceuticals products | Health Technology |
Viral Logic Systems Technology Corp.
 Viral Logic Systems Technology Corp. Pharmaceuticals: MajorHealth Technology Develops therapeutics for autoimmune and inflammatory disorders | Health Technology |
Intermediate Capital Group Plc (Private Equity)
Intermediate Capital Group Plc (Private Equity) Investment ManagersFinance ICG invests in companies located across the globe primarily in Western Europe and North America regions. The firm focuses across a broad range of sectors and industries. It participates in the form of mezzanine, debt and equity for buyouts, restructuring transactions, recapitalizations and whole-fund liquidity solutions. | Finance |
Resolve Therapeutics LLC
Resolve Therapeutics LLC BiotechnologyHealth Technology Develops biotechnology drugs | Health Technology |
Pieris Pharmaceuticals, Inc.
 Pieris Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and markets an anticalin-brand protein technology | Health Technology |
Cue Biopharma, Inc.
 Cue Biopharma, Inc. BiotechnologyHealth Technology Develops biopharmaceuticals | Health Technology |
Cirius Therapeutics, Inc.
 Cirius Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage pharmaceutical company that develops therapies | Health Technology |
LAVA Therapeutics NV
 LAVA Therapeutics NV Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops antibodies for the treatment of cancer | Health Technology |
Cereius, Inc.
 Cereius, Inc. BiotechnologyHealth Technology Develops novel radio-labeled therapeutics for treating solid tumor brain metastasis | Health Technology |
Bridge Valley Ventures LLP
Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures invests in companies located in the UK, Europe and North America. The firm focuses on oncology, neuroscience, immunology and rare diseases therapeutics, pharma/biotech sector. They provide financing for buyout transaction. | Finance |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Develops CAR-T therapy platform for cancer therapies | Technology Services |
Peptone Ltd.
Peptone Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products and provides business, domestic software development, data processing, hosting and biotechnology research and development services | Health Technology |
Itolerance, Inc.
 Itolerance, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops regenerative medicines | Health Technology |
